Brind.
  1. An executive order was issued to accelerate research related to drug policy in the US.
  2. Executive order shifts cannabis classification from Schedule I to Schedule III.

US cannabis rescheduling is expected to favor Tilray.

2 reports, 2 independent Updated Aug 28
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
3
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

US cannabis rescheduling is expected to favor Tilray.

Who's involved

What this event is mainly about
Tilray

How it developed

Newest first. Tap a step to see who reported it.
  1. Tilray benefits from the easing of federal research restrictions on cannabis.Sub-event
  2. US cannabis rescheduling is expected to favor Tilray.1 source
  3. DEA confirmation could accelerate cannabis rescheduling process.1 source

Keep exploring

Part of

Executive order shifts cannabis classification from Schedule I to Schedule III. All 2 developments

Within An executive order was issued to accelerate research related to drug policy in the US.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Insider MonkeyJefferies Raises Tilray (TLRY) Price Target on Potential Cannabis Rescheduling Tilray Brands, Inc. (NASDAQ:TLRY) ranks among the best sin stocks to buy right now. On August 25, Jefferies lifted its p
  • StockStoryTilray (TLRY) Stock Is Up, What You Need To Know Shares of cannabis company Tilray Brands (NASDAQ:TLRY) jumped 3.5% in the morning session on continued momentum that saw the stock rise significantly